In addition, the proportion of muscle-invasive bladder cancer was limited and ... value in locally advanced invasive or metastatic urothelial cancer.

Findings from the international FORT-2 clinical trial showed that a combination treatment including immunotherapy is safe and tolerable in patients with locally advanced or metastatic bladder cancer.

Bladder cancer is a cancer that develops in the bladder. It usually begins in the cells that line the inside of your bladder. Urothelial cells, the cells in the inner lining of your bladder are ...

Johnson & Johnson discontinues the Phase 3 SunRISe-2 trial for TAR-200 in bladder cancer, citing lack of superiority. Q3 ...

"These findings further support nivolumab plus GC as a standard first-line treatment option for cisplatin-eligible patients with unresectable or metastatic urothelial carcinoma," he said.

Results from cohort 2 of the TROPHY-U-01 study showed that sacitizumab govitecan led to rapid responses in patients with ...

GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

providing patients and clinicians with a urine test to detect and monitor recurrence of bladder cancer and upper tract urothelial carcinoma (UTUC). FLORENCE, Italy & SAN DIEGO & REHOVOT ...

In urothelial bladder cancer, increased T cell infiltration has been correlated with longer patient survival. In many cases, fibroblast growth factor receptor (FGFR) mutations are known to be ...